Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.
Saved in:
| Title: | Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial. |
|---|---|
| Authors: | Gebhart G; Nuclear Medicine Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium., Keyaerts M; Vrije Universiteit Brussel, Brussels, Belgium., Guiot T; Nuclear Medicine Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium., Flamen P; Nuclear Medicine Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium., Ruiz-Borrego M; Hospital Universitario Virgen del Rocío, Seville, Spain., Stradella A; Medical Oncology Department, Institut Català D'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain., Bermejo B; Hospital Clínico Universitario de Valencia, Valencia, Spain., Escriva-de-Romani S; Breast Cancer Group, Medical Oncology Department, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain., Calvo Martínez L; Medical Oncology Department, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain., Ribelles N; UGC Oncología Intercentros, Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Instituto de Investigaciones Biomédicas de Málaga, Málaga, Spain., Fernandez-Abad M; Medical Oncology Department, Ramón y Cajal Hospital, Madrid, Spain.; Alcala de Henares Medical University, Alcala de Henares, Madrid., Albacar C; Hospital Universitari Sant Joan de Reus, Reus, Spain., Colleoni M; IEO, European Institute of Oncology IRCCS, Milan, Italy., Garrigos L; Hospital Universitari Dexeus, Barcelona, Spain., Atienza de Frutos M; Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid, Spain., Dalenc F; Institut Claudius Regaud, IUCT-Oncopole, Toulouse Cancer Research Centre, INSERM, Toulouse, France., Prat A; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.; Translational Genomics and Targeted Therapies Group, IDIBAPS, Barcelona, Spain.; Department of Medicine, University of Barcelona, Barcelona, Spain., Marmé F; Medical Faculty Mannheim Heidelberg University, University Hospital Mannheim, Heidelberg, Germany., Schmid P; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.; Barts Hospital NHS Trust, London, United Kingdom., Kerrou K; Nuclear Medicine and PET Center Department, Tenon Hospital IUC-UPMC, APHP, Sorbonne University, Paris, France., Braga S; Hospital Vila Franca de Xira and Hospitals CUF Institute José de Mello Saúde, Lisbon, Portugal., Gener P; Medica Scientia Innovation Research, Barcelona, Spain., Sampayo-Cordero M; Medica Scientia Innovation Research, Barcelona, Spain., Cortés J; Medica Scientia Innovation Research, Barcelona, Spain.; International Breast Cancer Center, Quiron Group, Pangaea Oncology, Barcelona, Spain.; Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid, Spain., Pérez-García JM; Medica Scientia Innovation Research, Barcelona, Spain.; International Breast Cancer Center, Quiron Group, Pangaea Oncology, Barcelona, Spain., Llombart-Cussac A; Medica Scientia Innovation Research, Barcelona, Spain; antonio.llombart@maj3.health.; Hospital Universitario Arnau de Vilanova, Universidad Católica de Valencia, Valencia, Spain. |
| Source: | Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2024 May 01; Vol. 65 (5), pp. 708-713. Date of Electronic Publication: 2024 May 01. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Electronic Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38575192 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Optimal [<superscript>18</superscript>F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Gebhart+G%22">Gebhart G</searchLink>; Nuclear Medicine Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Keyaerts+M%22">Keyaerts M</searchLink>; Vrije Universiteit Brussel, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Guiot+T%22">Guiot T</searchLink>; Nuclear Medicine Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Flamen+P%22">Flamen P</searchLink>; Nuclear Medicine Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Ruiz-Borrego+M%22">Ruiz-Borrego M</searchLink>; Hospital Universitario Virgen del Rocío, Seville, Spain.<br /><searchLink fieldCode="AU" term="%22Stradella+A%22">Stradella A</searchLink>; Medical Oncology Department, Institut Català D'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Bermejo+B%22">Bermejo B</searchLink>; Hospital Clínico Universitario de Valencia, Valencia, Spain.<br /><searchLink fieldCode="AU" term="%22Escriva-de-Romani+S%22">Escriva-de-Romani S</searchLink>; Breast Cancer Group, Medical Oncology Department, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Calvo+Martínez+L%22">Calvo Martínez L</searchLink>; Medical Oncology Department, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain.<br /><searchLink fieldCode="AU" term="%22Ribelles+N%22">Ribelles N</searchLink>; UGC Oncología Intercentros, Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Instituto de Investigaciones Biomédicas de Málaga, Málaga, Spain.<br /><searchLink fieldCode="AU" term="%22Fernandez-Abad+M%22">Fernandez-Abad M</searchLink>; Medical Oncology Department, Ramón y Cajal Hospital, Madrid, Spain.; Alcala de Henares Medical University, Alcala de Henares, Madrid.<br /><searchLink fieldCode="AU" term="%22Albacar+C%22">Albacar C</searchLink>; Hospital Universitari Sant Joan de Reus, Reus, Spain.<br /><searchLink fieldCode="AU" term="%22Colleoni+M%22">Colleoni M</searchLink>; IEO, European Institute of Oncology IRCCS, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Garrigos+L%22">Garrigos L</searchLink>; Hospital Universitari Dexeus, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Atienza+de+Frutos+M%22">Atienza de Frutos M</searchLink>; Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Dalenc+F%22">Dalenc F</searchLink>; Institut Claudius Regaud, IUCT-Oncopole, Toulouse Cancer Research Centre, INSERM, Toulouse, France.<br /><searchLink fieldCode="AU" term="%22Prat+A%22">Prat A</searchLink>; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.; Translational Genomics and Targeted Therapies Group, IDIBAPS, Barcelona, Spain.; Department of Medicine, University of Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Marmé+F%22">Marmé F</searchLink>; Medical Faculty Mannheim Heidelberg University, University Hospital Mannheim, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Schmid+P%22">Schmid P</searchLink>; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.; Barts Hospital NHS Trust, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Kerrou+K%22">Kerrou K</searchLink>; Nuclear Medicine and PET Center Department, Tenon Hospital IUC-UPMC, APHP, Sorbonne University, Paris, France.<br /><searchLink fieldCode="AU" term="%22Braga+S%22">Braga S</searchLink>; Hospital Vila Franca de Xira and Hospitals CUF Institute José de Mello Saúde, Lisbon, Portugal.<br /><searchLink fieldCode="AU" term="%22Gener+P%22">Gener P</searchLink>; Medica Scientia Innovation Research, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Sampayo-Cordero+M%22">Sampayo-Cordero M</searchLink>; Medica Scientia Innovation Research, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Cortés+J%22">Cortés J</searchLink>; Medica Scientia Innovation Research, Barcelona, Spain.; International Breast Cancer Center, Quiron Group, Pangaea Oncology, Barcelona, Spain.; Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Pérez-García+JM%22">Pérez-García JM</searchLink>; Medica Scientia Innovation Research, Barcelona, Spain.; International Breast Cancer Center, Quiron Group, Pangaea Oncology, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Llombart-Cussac+A%22">Llombart-Cussac A</searchLink>; Medica Scientia Innovation Research, Barcelona, Spain; antonio.llombart@maj3.health.; Hospital Universitario Arnau de Vilanova, Universidad Católica de Valencia, Valencia, Spain. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%220217410%22">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</searchLink> [J Nucl Med] 2024 May 01; Vol. 65 (5), pp. 708-713. <i>Date of Electronic Publication: </i>2024 May 01. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Society+of+Nuclear+Medicine%22">Society of Nuclear Medicine </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0217410 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1535-5667 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201615505%22">01615505 </searchLink><i>NLM ISO Abbreviation: </i>J Nucl Med <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38575192 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.2967/jnumed.123.266384 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 708 Titles: – TitleFull: Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Gebhart G – PersonEntity: Name: NameFull: Keyaerts M – PersonEntity: Name: NameFull: Guiot T – PersonEntity: Name: NameFull: Flamen P – PersonEntity: Name: NameFull: Ruiz-Borrego M – PersonEntity: Name: NameFull: Stradella A – PersonEntity: Name: NameFull: Bermejo B – PersonEntity: Name: NameFull: Escriva-de-Romani S – PersonEntity: Name: NameFull: Calvo Martínez L – PersonEntity: Name: NameFull: Ribelles N – PersonEntity: Name: NameFull: Fernandez-Abad M – PersonEntity: Name: NameFull: Albacar C – PersonEntity: Name: NameFull: Colleoni M – PersonEntity: Name: NameFull: Garrigos L – PersonEntity: Name: NameFull: Atienza de Frutos M – PersonEntity: Name: NameFull: Dalenc F – PersonEntity: Name: NameFull: Prat A – PersonEntity: Name: NameFull: Marmé F – PersonEntity: Name: NameFull: Schmid P – PersonEntity: Name: NameFull: Kerrou K – PersonEntity: Name: NameFull: Braga S – PersonEntity: Name: NameFull: Gener P – PersonEntity: Name: NameFull: Sampayo-Cordero M – PersonEntity: Name: NameFull: Cortés J – PersonEntity: Name: NameFull: Pérez-García JM – PersonEntity: Name: NameFull: Llombart-Cussac A IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 05 Text: 2024 May 01 Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 1535-5667 Numbering: – Type: volume Value: 65 – Type: issue Value: 5 Titles: – TitleFull: Journal of nuclear medicine : official publication, Society of Nuclear Medicine Type: main |
| ResultId | 1 |
